Insider Selling: Labcorp (NYSE:LH) CEO Sells $1,495,807.53 in Stock

Labcorp Holdings Inc. (NYSE:LH) CEO Adam Schechter sold 4,669 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Stock Down 1.4%

Labcorp stock opened at $318.02 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $325.58. The firm has a fifty day moving average price of $286.24 and a two-hundred day moving average price of $274.67. The firm has a market cap of $25.79 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 1.87 and a beta of 0.87.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the business posted $4.35 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, analysts forecast that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio is 23.82%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on LH shares. Morgan Stanley boosted their price objective on shares of Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. increased their target price on shares of Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Mizuho set a $355.00 price target on Labcorp in a research note on Monday. Finally, Barclays upped their price target on Labcorp from $290.00 to $320.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $330.00.

Institutional Investors Weigh In On Labcorp

Institutional investors have recently bought and sold shares of the business. UBS Group AG raised its stake in Labcorp by 2.2% during the fourth quarter. UBS Group AG now owns 495,535 shares of the medical research company’s stock worth $124,320,000 after acquiring an additional 10,706 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Labcorp by 106.5% in the 1st quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company’s stock valued at $15,470,000 after purchasing an additional 29,899 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Labcorp by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock valued at $534,023,000 after purchasing an additional 13,775 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Labcorp by 61.3% in the 4th quarter. CIBC Asset Management Inc now owns 19,974 shares of the medical research company’s stock worth $5,011,000 after purchasing an additional 7,592 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Labcorp by 103.1% in the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after purchasing an additional 2,719,475 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.